Page 6 - Pharma Industry

Wockhardt exits US generics biz, to focus on innovative portfolio

Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.

Anthem Biosciences expands manufacturing capacity ahead of ₹3,395-cr IPO

CRDMO firm Anthem Biosciences expands peptide and API production, with Unit 4 under development, as it prepares for a Rs 3,395-crore IPO opening on July 14

Trump threatens 200% pharma, 50% copper tariffs: What it means for India

As trade tensions escalate under Donald Trump, India finds itself in the crosshairs once again. Donald Trump's proposed duties target two of India's biggest export sectors - pharmaceuticals and copper

India's pharma exports to US surged in March amid tariff concerns

India's pharma exports saw a significant rise in March, driven by fears of impending US tariffs. Industry experts anticipate impact of potential reciprocal tariffs on India's future export strategy

GMP, NSQ compliance: MSME pharmaceutical companies seek financial aid

Pharma MSMEs seek Rs 50 crore handholding and extension for GMP compliance under revised Schedule M, citing challenges in adhering to regulatory and quality standards

HC-ordered expert panel for weight loss drug may be set up by mid-July

A Delhi HC directive to examine unregulated use of weight loss drugs may lead to a CDSCO expert panel by mid-July, possibly led by DCGI with pharma and govt representation

Pharma GCCs tap artificial intelligence to fast-track drug discovery

They are not just cutting down drug development time, but also the cost involved in it. AI is reshaping how drugs and therapies are developed

Lupin carves out consumer healthcare biz into wholly owned subsidiary

The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.

KKR's JB Chemicals exit cements its strong healthcare track record

The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020

Biological E to make HPV9 vaccine under licensing pact with Recbio

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in UNICEF and PAHO tenders

Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore

India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20

Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK

NPPA fixes retail prices for 41 drug combinations, including empagliflozin

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments, citing steep price drops and growing generic availability

Zydus signs deal with Agenus for BOT and BAL cancer therapies in India

Zydus Lifesciences has partnered with Agenus to license the cancer immunotherapies Botensilimab and Balstilimab for India and Sri Lanka, expanding its oncology offerings

Sun Pharma halts development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis

Medical representatives barred from govt hospitals to stop pharma influence

The Centre's move seeks to curb the influence of pharmaceutical companies. Sharing of information must now happen through email or other digital platforms

Lupin signs licensing deal with SteinCares for ranibizumab in LatAm

Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina

Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%

The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar

Strong growth seen for Divi's Laboratories, but upside capped by valuations

Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range